Share

Bone disease breakthrough

Emil Kakkis, Ultragenyx founder & CEO, discusses the beginning of its drug KRN23's phase 2 pediatric study to treat 30 kids with bone disorder X-linked hypophosphatemia (XLH).
02:29
Thu, Jun 26 20145:45 PM EDT